Welcome to SwanBio Therapeutics

SwanBio Therapeutics is a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of neurological diseases. We are driven by an unrelenting passion to solve difficult challenges, and a belief that meaningful discovery is born of curiosity, collaboration, and compassion.

Founded by proven industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialization expertise.

OUR SCIENCE

SwanBio Therapeutics is dedicated to developing genetic medicines for the treatment of serious neurological diseases with significant unmet need.

Nearly 27 million Americans are currently afflicted by one of over 1,000 neurological diseases, which lead to tremendous suffering, life-limiting disability, and expansive societal burden. The impact of these diseases on patients and their families, friends, and communities affects more than 100 million Americans.

More >>

LEADERSHIP TEAM

SwanBio Therapeutics brings together the vast experience of the unique combination of the founders in science, technology, clinical applications, and manufacturing.

TOM ANDERSON

CEO

RACHEL SALZMAN, DVM

President Co-Founder,
Chief Portfolio Development Officer

KAREN KOZARSKY, PHD

Chief Scientific Officer
Co-Founder

MICHAEL ALEXANDER, JD, PH.D.

General Counsel – SwanBio Therapeutics, Inc.

FLORIAN S. EICHLER, MD

Chair of Clinical
Advisory Board, Co-Founder

INVESTORS

Syncona Logo

SwanBio Therapeutics is funded by Syncona Ltd., a leading FTSE250 company that invests in, and builds, global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating attractive returns for shareholders. More >>

Partners Logo

Partners Innovation Fund, the venture fund for Mass General and Brigham and Women’s, the principal teaching affiliates of Harvard Medical School, is also a SwanBio Therapeutics investor. The fund accelerates technology development that enhances healthcare quality, cost and outcomes. More >>

CAREERS

SwanBio’s open, innovative culture enables team members to become catalysts for scientific discovery, clinical application, and business success. With offices in Boston and Philadelphia, SwanBio provides extraordinary career opportunities for talented individuals.

Learn More